rs754295034
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 3P and 4B. PM1PP2BP4_ModerateBP6BS2_Supporting
The NM_001042492.3(NF1):c.181A>G(p.Ile61Val) variant causes a missense change. The variant allele was found at a frequency of 0.0000254 in 1,613,598 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001042492.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NF1 | NM_001042492.3 | c.181A>G | p.Ile61Val | missense_variant | Exon 2 of 58 | ENST00000358273.9 | NP_001035957.1 | |
NF1 | NM_000267.3 | c.181A>G | p.Ile61Val | missense_variant | Exon 2 of 57 | NP_000258.1 | ||
NF1 | NM_001128147.3 | c.181A>G | p.Ile61Val | missense_variant | Exon 2 of 15 | NP_001121619.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152106Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251188Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135754
GnomAD4 exome AF: 0.0000239 AC: 35AN: 1461492Hom.: 0 Cov.: 32 AF XY: 0.0000275 AC XY: 20AN XY: 727060
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152106Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74312
ClinVar
Submissions by phenotype
not specified Uncertain:1
Variant summary: NF1 c.181A>G (p.Ile61Val) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 251188 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To the best of our knowledge, c.181A>G has not been reported in the literature in individuals affected with Neurofibromatosis Type 1. Three recent case-control studies of Breast cancer and Biliary tract cancer did not found this variant in the disease cohorts but reported in the controls (example, Momozawa_2018, Okawa_2023, Dorling_2021). These report(s) do not provide unequivocal conclusions about association of the variant with Neurofibromatosis Type 1 and other NF1-related disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 30287823, 36243179, 33471991). ClinVar contains an entry for this variant (Variation ID: 457548). Based on the evidence outlined above, the variant was classified as VUS-possibly benign. -
NF1-related disorder Uncertain:1
The NF1 c.181A>G variant is predicted to result in the amino acid substitution p.Ile61Val. This variant was reported in an individual with Breast cancer, female (Momozawa et al 2018. PubMed ID: 30287823, Supplementary Data 1). This variant is reported in 0.0046% of alleles in individuals of European (Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/17-29483121-A-G). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Neurofibromatosis, type 1 Benign:1
- -
not provided Benign:1
In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 30287823) -
Hereditary cancer-predisposing syndrome;CN230736:Cardiovascular phenotype Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at